ATREON joins Future of Health Grant at Level 3
ATREON receives programme support for remote inflammatory arthritis monitoring.
ATREON was selected for Level 3 of the Future of Health Grant in the spring cohort announced on March 5, 2026. The Swiss company, previously supported at Level 2 under the DETECTRA name, receives further equity-free programme support. Its individual allocation was not disclosed.
The company develops remote monitoring for inflammatory arthritis. Patients record symptoms and hand images between appointments, providing care teams with a more regular view of their condition. Its DETECTRA research programme investigates digital markers of joint swelling.
The support combines coaching with access to healthcare experts and potential clinical partners as ATREON develops and validates its technology.